DOI : 10.1055/s-00000094

Zeitschrift für Gastroenterologie

Issue 05 · Volume 53 · May 2015 DOI: 10.1055/s-005-29116


48. Jahrestagung und 26. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH)
Salzburg, 18. – 20. Juni 2015

Kongresspräsident: Univ.-Prof. Dr. Michael Trauner – Kongresssekretäre: Univ.-Prof. Dr. Harald Hofer, Priv.-Doz. Dr. Wolfgang Miehsler – Fortbildungskurs: Univ.-Prof. Dr. Peter Ferenci, Assoc. Prof. Dr. Christoph Steininger
Abstracts (HTML) List of Authors
P49
Zöhrer, E; Heckmann, M; Fröhlich-Reiterer, E; Jasser-Nitsche, H; Fauler, G; Scharnagl, H; Stojakovic, T; Jahnel, J: Serum bile acids in adolescents with type 1 diabetes: a new marker for glycaemic control?
P50
Mandorfer, M; Kozbial, K; Freissmuth, C; Schwabl, P; Stättermayer, AF; Reiberger, T; Beinhardt, S; Schwarzer, R; Trauner, M; Ferlitsch, A; Hofer, H; Peck-Radosavljevic, M; Ferenci, P: Interferon-free regimens overcome the effect of portal hypertension on virologic response
P51
Mandorfer, M; Bota, S; Schwabl, P; Bucsics, T; Pfisterer, N; Goliasch, G; Fuhrmann, V; Horvatits, T; Ferlitsch, A; Sieghart, W; Trauner, M; Peck-Radosavljevic, M; Reiberger, T: The presence of echocardiographic abnormalities increases mortality in patients with spontaneous bacterial peritonitis
P52
Gschwantler, M; Laferl, H; Vogel, W; Korak, W; Moser, S; Hofer, H; Bauer, B; Schleicher, M; Bognar, B; Bischof, M; Stauber, R; Maieron, A; Ferenci, P: Efficacy of Peginterferon plus Ribavirin in patients receiving Opioid substitution therapy – final results of the Austrian Peghope-study
P53
Moser, S; Karpi, A; Gutic, E; Schleicher, M; Hellmich, B; Gschwantler, M: Access to reimbursement of interferon-free all-oral regimens for patients with chronic Hepatitis C in Austria
P54
Schütz, A; Moser, S; Reisinger, M; Karpi, A; Marchart, K; Gutic, E; Ambrosch, S; Schleicher, M; Haltmayer, H; Gschwantler, M: Direct observed therapy of chronic Hepatitis C with an interferon-free all-oral regimen at a low-threshold drug treatment facility – a new concept for treatment of patients with borderline compliance receiving Opioid substitution therapy
P55
Kienbacher, C; Traussnigg, S; Halilbasic, E; Fuchs, C; Dolak, W; Steindl-Munda, P; Stojakovic, T; Fauler, G; Claudel, T; Trauner, M: Disturbed energy metabolism and lipid profile after a 4 week high oral fructose challenge: potential role of bile acids?
P56
Gschwantler, M; Asselah, T; Moreno, C; Sarrazin, C; Foster, GR; Craxi, A; Buggisch, P; Ryan, R; Lenz, O; Van Dooren, G; Lonjon-Domanec, I; Schlag, M; Buti, M: Shortening overall treatment to 12 weeks of Simeprevir (SMV) plus PEG-IFN/RBV in treatment-naïve chronic Hepatitis C (CHC) Genotype 1 patients: assessment of baseline and week 2 on-treatment predictors of SVR
P57
Staufer, K; Stauber, R; Theek, C; Kienbacher, C; Lackner, C; Steindl-Munda, P; Schulz-Knappe, P; Trauner, M: Autoantikörper – Signaturen zur non-invasiven Diagnostik der nicht-alkoholischen Fettlebererkrankung
P58
Karpi, A; Moser, S; Gutic, E; Schleicher, M; Hellmich, B; Gschwantler, M: Efficacy of interferon-free all-oral regimens in the treatment of chronic Hepatitis C outside from clinical trials – a “real life experience”
P59
Mandorfer, M; Steiner, S; Schwabl, P; Aichelburg, MC; Grabmeier-Pfistershammer, K; Rieger, A; Trauner, M; Reiberger, T; Peck-Radosavljevic, M: Interferon and ribavirin-free therapy with sofosbuvir and daclatasvir in a real-life cohort of difficult-to-treat HIV/HCV-coinfected patients
P60
Strasser, M; Haufe, H; Stadlmayr, A; Ferenci, P; Patsch, W; Datz, C; Aigner, E: Natural course of subjects with elevated liver enzymes and normal liver histology
P61
Beinhardt, S; Eder, M; Marculescu, R; Strassl, R; Stättermayer, A; Stift, J; Kozbial, K; Freissmuth, C: High prevalence of Vitamin D deficiency in patients with autoimmune Hepatitis: impact on clinical presentation and response to treatment
P62
Beinhardt, S; Kozbial, K; Schmidt, A; Freissmuth, C; Mandorfer, M; Strassl, R; Al-Zoairy, R: Real life experience with Interferon/Ribavirin-free antiviral treatment in renal transplant recipients and endstage renal disease-patients on dialysis infected with Hepatitis C virus
P63
Beinhardt, S; Mandorfer, M; Payer, BA; Stättermayer, AF: Usefulness of interferon Lambda-4, HLA Class II Polymorphysims and Killer-Immunglobuline-Like Recptor-2DL3:C1/C1 to predict spontaneous clearance of acute Hepatitis C virus infection
P64
Beinhardt, S; Freissmuth, C; Al-Zoairy, R; Kozbial, K; Hamethner, S; Hametner, S; Sern, R: Efficacy and safety of IFN-free antiviral therapy in patients with HCV recurrence after liver transplantation: real-life experience from Austria
P65
Scheiner, B; Mandorfer, M; Schwabl, P; Payer, B; Aichelburg, M; Grabmeier-Pfistershammer, K; Stättermayer, A; Ferenci, P; Trauner, M; Peck-Radosavljevic, M; Reiberger, T: The presence of a PNPLA3 (rs738409) single nucleotide polymorphism (SNP) is not associated with increased risk for fibrosis, portal hypertension, and hepatic steatosis in HIV/HCV-coinfected patients
P66
Mayr, C; Wagner, A; Neureiter, D; Pichler, M; Ritter, M; Illig, R; Berr, F; Kiesslich, T: Green tea catechin epigallocatechin gallate causes apoptosis and shows potential synergism with cisplatin in biliary tract cancer cells
P67
Mayr, C; Wagner, A; Beyreis, M; Illig, R; Berr, F; Pichler, M; Di Fazio, P; Neureiter, D; Kiesslich, T: Treatment of biliary tract cancer cells with polycomb repressive complex 1 inhibitor PTC-209 reduces putative cancer stem cell population and causes cell cycle arrest
P68
Krones, E; Rainer, F; Blesl, A; Pollheimer, MJ; Zollner, G; Fickert, P: Entzündlicher IgG4-positiver Pseudotumor der Lunge bei primär sklerosierender Cholangitis (PSC)
P69
Vogel, W; Laferl, H; Plankensteiner, G; Nitzlader, M: Efficacy and Safety of Telbivudine as First-Line Therapy in Patients With Compensated Chronic Hepatitis B
P70
Feldman, A; Eder, SK; Felder, TK; Stadlmayr, A; Datz, C; Aigner, E: A distinct profile of Lyso-Phosphatidylcholines and amino acids characterizes NAFLD in lean subjects
P71
Wilhelmer, P; Krones, E; Racedo, SM; Fickert, P: Differentielle Effekte von Gallensäuren auf Tubulus- und Sammelrohrepithelzellen
P72
Stern, R; Freissmuth, C; Kozbial, K; Hametner, S; Al-Zoairy, R; Moser, S; Laferl, H; Stauber, R; Zoller, H; Maieron, A; Vogel, W; Gschwantler, M; Hofer, H; Ferenci, P: Safety and efficacy of Interferon//Ribavirin free therapy in Septuagenerians and Octogenerians with chronic Hepatitis C
P73
Pollheimer, MJ; Racedo, S; Marshall, D; Silbert, D; Gumhold, J; Trauner, M; Fickert, P: Seneszenzstimuli und Hypoxie induzieren LOXL2 und HIF1alpha Expression und führen zur Repression von E-Cadherin in Gallengangsepithelzellen
P74
Traussnigg, S; Kienbacher, C; Gajdošík, M; Valkovič, L; Ferenci, P; Wrba, F; Stift, J; Trattnig, S; Krššák, M; Trauner, M: Ultra-high-field MR-spectroscopy in NAFLD as in-vivo tool for monitoring changes in fat and energy metabolism with potential identification of NASH and advanced fibrosis by saturation transfer technique
P75
Eder, M; Beinhardt, S; Strassl, R; Stättermayer, A; Freissmuth, C; Kozbial, K; Holzmann, H; Ferenci, P; Trauner, M; Hofer, H: Seroprevalence of Hepatitis E Virus in patients with Autoimmune Hepatitis
P76
Wieser, V; Adolph, TE; Grander, C; Grabherr, F; Gerner, R; Enrich, B; Bichler, A; Lichtmannegger, L; Moschen, AR; Tilg, H: Restoration of low adipose PNPLA3 concentrations after bariatric surgery
P77
Lemesch, S; Spindelboeck, W; Öttl, K; Payerl, D; Stauber, R; Leber, B; Stadlbauer, V: Humanes Non-Mercaptalbumin: methodischer Aspekt eines Prognosemarkers bei ACLF
P78
Ferenci, P; Asselah, T; Moreno, C; Craxi, A; Sanai, F; Ryan, R; Lenz, O; Van Dooren, G; Lonjon-Domanec, I; Schlag, M; Buti, M: Shortening overall treatment to 12 weeks of SIMEPREVIR plus pegylated-interferon/ribavirin according to early virologic response in treatment-naïve patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis
P79
Fuchs, CD; Baghdasaryan, A; Österreicher, CH; Lemberger, U; Graffner, H; Krones, E; Fickert, P; Wahlström, A; Marschall, H; Paumgartner, G; Trauner, M: Inhibition of intestinal bile acid absorption by ASBT inhibitor A4250 protects against cholestatic liver and bile duct injury in MDR2-/- mouse model of sclerosing Cholangitis
P80
Stättermayer, AF; Eder, M; Beinhardt, S; Kozbial, K; Freissmuth, C; Wrba, F; Trauner, M; Ferenci, P; Hofer, H: Impact of SNP rs2187668 in HLA-DQA1 on clinical presentation and treatment response in patients with type-1 autoimmune hepatitis
P81
Bucsics, T; Diermayr, M; Feldner-Busztin, M; Schwabl, P; Mandorfer, M; Karnel, F; Karner, J; Angermayr, B; Cejna, M; Sieghart, W; Ferlitsch, A; Peck-Radosavljevic, M; Reiberger, T: Efficacy of transjugular intrahepatic portosystemic shunts (TIPS) for controlling variceal bleeding in patients with cirrhosis and portal hypertension
P82
Freissmuth, C; Stättermayer, AF; Kozbial, K; Beinhardt, S; Eder, M; Munda, P; Trauner, M; Ferenci, P; Hofer, H: Serum lipid parameters in patients with chronic hepatitis C during IFN-free treatment: effect of HCV genotype and cirrhosis
P83
Bucsics, T; Feldner-Busztin, M; Diermayr, M; Schwabl, P; Mandorfer, M; Karnel, F; Karner, J; Angermayr, B; Cejna, M; Sieghart, W; Ferlitsch, A; Peck-Radosavljevic, M; Reiberger, T: Short-term complications after TIPS-implantation in patients with liver cirrhosis and portal hypertension
P84
Wakolbinger, R; Nia, A; Resch, H; Bodlaj, G; Muschitz, C: Pilotstudie: Knochendichte und Knochenmikroarchitektur bei Patienten mit Leberzirrhose
P85
Viveiros, A; Schaefer, B; Haschka, D; Ravasi, G; Finkenstedt, A; Nachbaur, K; Henninger, B; Vogel, W; Zoller, H: Functional and clinical implications of ferroportin mutation p.Arg178Gln
P86
Steinacher, D; Claudel, T; Stojakovic, T; Trauner, M: NorUDCA improves liver injury and glucose sensitivity in a mouse model of obesity and steatosis
P87
Freissmuth, C; Beinhardt, S; Stern, R; Kozbial, K; Eder, M; Stättermayer, AF; Trauner, M; Ferenci, P; Hofer, H: Changes in renal function parameters during nucleos(t)ide analogues (NA) treatment in patients with chronic hepatitis B
P88
Niederseer, D; Stadlmayr, A; Huber-Schönauer, U; Lederer, D; Patsch, W; Aigner, E; Datz, C: Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease predicts cardiovascular risk in a large screening cohort
P89
Durchschein, F; Krones, E; Pollheimer, M; Rast, C; Glänzer, D; Wagner, M; Zollner, G; Fickert, P: Proximal Selektive Vagotomie in Mdr2 Genknockout Mäusen führt zu einer Verminderung der Cholestase, des Leberschadens und zur Verringerung der duktularen Proliferation
P90
Fuchs, CD; Paumgartner, G; Wahlström, A; Stojakovic, T; Marschall, H; Trauner, M: Absence of BSEP/ABCB11 protects from cholestatic liver and bile duct injury in a mouse model of sclerosing Cholangitis
P91
Horvath, A; Leber, B; Krones, E; Zollner, G; Fickert, P; Stauber, RE; Lemesch, S; Spindelboeck, W; Durchschein, F; Douschan, P; Stiegler, P; Stojakovic, T; Fauler, G; Stadlbauer, V: Serum bile acids in cirrhosis depend on aetiology
P92
Horvath, A; Leber, B; Schmerboeck, B; Stadlbauer, V: Endotoxinmessung bei Leberzirrhose: Ein Methodenvergleich
P93
Panzitt, K; Marschall, H; Trauner, M; Fickert, P; Wagner, M: Effekte von Ursodeoxycholsäure und Rifampicin auf Autophagie in der Leber
P94
Bucsics, T; Mandorfer, M; Schwabl, P; Bota, S; Trauner, M; Sieghart, W; Ferlitsch, A; Peck-Radosavljevic, M; Reiberger, T: Identifying the trigger matters – outcome of severe acute kidney injury in patients with cirrhosis and ascites
P95
Dorn, L; Finkenstedt, A; Viveiros, A; Prokop, W; Griesmacher, A; Vogel, W; Zoller, H: Transferrin als unabhängiger Prädiktor für das Überleben bei Patienten mit Leberzirrhose
P96
Bota, S; Purevsambuu, T; Hucke, F; Reiberger, T; Ferlitsch, A; Hofer, H; Sieghart, W; Peck-Radosavljevic, M: A new algorithm for predicting the hepatocellular carcinoma occurrence in cirrhotic patients
P97
Finkenstedt, A; Vikoler, A; Portenkirchner, M; Mülleder, K; Moser, P; Peterson, J; Bale, R; Freund, M; Luger, A; Vogel, W; Schneeberger, S; Graziadei, I; Zoller, H; Glodny, B: Exzellentes Langzeitüberleben nach Lebertransplantation bei Patienten mit BCLC Intermediate Stage B Hepatozellulärem Karzinom und Ansprechen auf neoadjuvante Therapie
P98
Spindelboeck, W; Buder, R; Graziadei, I; Peck-Radosavljevic, M; Keil, F; Tinchon, C; van Zijl, F; Stauber, RE: INSIGHT-Studie Österreich: Outcome – Daten zur Therapie des hepatozellulären Karzinoms (HCC) mit Sorafenib
P99
Kozbial, K; Freissmuth, C; Al-Zoairy, R; Moser, S; Laferl, H; Hametner, S; Stauber, R; Strasser, M; Bamberger, T; Beinhardt, S; Stättermayer, A; Stern, R; Eder, M; Mandorfer, M; Zoller, H; Vogel, W; Graziadei, I; Strassl, R; Maieron, A; Gschwantler, M; Ferlitsch, A; Peck-Radosavljevic, M; Trauner, M; Ferenci, P; Hofer, H: Interferon-free Sofosbuvir containing treatment regimens in a real-life cohort of chronic Hepatitis C patients with cirrhosis
P100
Kozbial, K; Beinhardt, S; Freissmuth, C; Stättermayer, A; Stern, R; Munda, P; Trauner, M; Ferenci, P; Hofer, H: Decrease in liver fibrosis after achieving SVR in patients with chronic Hepatitis C infection
P101
Schwabl, P; Brusilovskaya, K; Riedl, F; Bauer, D; Strobel, B; Fida, S; Supper, P; Hayden, H; Trauner, M; Peck-Radosavljevic, M; Reiberger, T: The soluble guanylyl cyclase stimulator riociguat reduces liver fibrosis and portal pressure in cirrhotic rats
P102
Schwabl, P; Hambruch, E; Payer, BA; Schubert, TL; Strobel, B; Fida, S; Wagner, M; Garnys, L; Trauner, M; Peck-Radosavljevic, M; Kremoser, C; Reiberger, T: The FXR agonist PX20606 reduces liver damage, fibrosis and portal hypertension in cirrhotic rats